News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 19, 2023, 22:47 ET Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating the...

Mar 19, 2023, 22:43 ET Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating the...

Mar 13, 2023, 23:04 ET U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing...

Mar 13, 2023, 23:01 ET U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing...

Mar 05, 2023, 21:53 ET FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and grants Priority Review: BioArctic

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's...

Mar 05, 2023, 21:50 ET FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and grants Priority Review: BioArctic

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's...

Feb 28, 2023, 01:27 ET BioArctic hires Anders Martin-Löf as new CFO

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO. Anders Martin-Löf...

Feb 28, 2023, 01:25 ET BioArctic hires Anders Martin-Löf as new CFO

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO. Anders Martin-Löf...

Feb 27, 2023, 21:39 ET Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name ...

Feb 27, 2023, 21:37 ET Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name ...

Jan 29, 2023, 22:56 ET BioArctic: Lecanemab receives priority review status in Japan

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for...

Jan 29, 2023, 22:54 ET BioArctic: Lecanemab receives priority review status in Japan

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for...

Jan 26, 2023, 21:44 ET European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArctic

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing...

Jan 26, 2023, 21:42 ET European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArctic

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing...

Jan 25, 2023, 03:34 ET Invitation to presentation of BioArctic's fourth quarter report for October - December 2022 on October 20 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2022 on Friday, February 3,...

Jan 25, 2023, 03:32 ET Invitation to presentation of BioArctic's fourth quarter report for October - December 2022 on October 20 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2022 on Friday, February 3,...

Jan 15, 2023, 21:58 ET BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for...

Jan 15, 2023, 21:56 ET BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for...

Jan 10, 2023, 22:01 ET BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in the EU

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application (MAA)...

Jan 10, 2023, 21:58 ET BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in the EU

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application (MAA)...

Jan 08, 2023, 22:01 ET FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...

Jan 08, 2023, 21:56 ET FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...

Jan 08, 2023, 21:55 ET BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today they have submitted a supplemental Biologics License Application...

Jan 08, 2023, 21:53 ET BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today they have submitted a supplemental Biologics License Application...

Jan 02, 2023, 02:33 ET BioArctic moves to Nasdaq Stockholm Large Cap

As of today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will move to the Large Cap listing on the Nasdaq Stockholm stock exchange. "The move to...